David Hallal Becomes Chief Executive Officer of Alexion

On April 1, 2015, David Hallal assumed the role of Chief Executive Officer of Alexion. He succeeds Leonard Bell, M.D., who has retired as CEO but will continue to serve as Chairman of the Board. Dr. Bell was the principal founder of Alexion in 1992 and has served as CEO for the past 23 years.

“Lenny is an inspirational leader who has developed a company-wide commitment to innovation, created our patient-focused culture, and instilled exquisite discipline and operational excellence that have driven our remarkable success over the last two decades. I am deeply honored to become Alexion’s second CEO and I look forward to leading our deeply experienced executive team and talented and dedicated staff as we serve patients around the world,” said Mr. Hallal.

Mr. Hallal will lead Alexion into the Company’s next stage of its global growth and innovation. “As I look at the company today, I see more than $2 billion in revenues, the potential launch of our next product later this year, the most robust pipeline in our history with 3 ongoing registration programs and 4 additional highly innovative candidates in development, global leadership in complement science to serve patients through the next two decades, a strong foundation for future growth with an additional 17 pre-clinical development programs spanning diverse modalities and therapeutic areas, and a balance sheet aligned with our strong growth objectives,” added Mr. Hallal. “We have never been better positioned to leverage our unique 50-country commercial platform to drive future product expansion.”

Prior to becoming CEO, Mr. Hallal was Chief Operating Officer, leading key enterprise-wide initiatives that focused on diverse aspects of Alexion’s operations. Mr. Hallal joined Alexion in 2006 to launch the company’s commercial operations and has led the highly successful introductions of Soliris for both PNH and aHUS, while also building Alexion’s 50-country operating platform.